Lipid-based nanoparticle technologies for liver targeting

Böttger, Roland; Pauli, Griffin; Chao, Po-Han; Fayez, Nojoud Al; Hohenwarter, Lukas; Li, Shyh-Dar

doi:10.1016/j.addr.2020.06.017

Cited by 141 publications

(112 citation statements)

References 253 publications

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…To enhance the cellular uptake in dendritic cells for enhanced immune response, lipid-based nanoparticles have been conjugated with cell-penetrating peptides such as R8 and GALA [ 62 ]. Many other ligands of dendritic cell receptors (for review see [ 63 ]) and of liver cells (for review see [ 17 ]) have been developed for targeting purposes and are listed below. Fusogenic peptides such as DOPE have also shown to improve membrane fusion, and thus cell uptake [ 64 ].…”

Section: Lipid-based Nanoparticlesmentioning

confidence: 99%

“…In recent years, lipid-based nanoparticles have emerged as the most effective carrier for the delivery of cargo to target cells, which have translated into clinical success. The analytical characterization, the basic technological concepts and highlights have been reviewed extensively before [ 17 , 38 , 39 , 70 ]. The current review will focus on the translation of lipid-based nanoparticles into the clinic.…”

Section: Lipid-based Nanoparticlesmentioning

confidence: 99%

“…This advancement was achieved in 2018, with the FDA approval of Onpattro ® ((Alnylam Pharmaceuticals, Inc., Cambridge, MA, USA) and Sanofi Genzyme (Cambridge, MA, USA)), consisting of siRNA encapsulated in lipid nano-particles (LNPs) ( Figure 1 a) for the treatment polyneuropathy in people with hereditary transthyretin-mediated amyloidosis [ 12 , 13 , 14 , 15 ]. This LNP is made of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)-butanoate (DLin-MC3-DMA) lipid, disterarolyphosphatidychloline (DSPC), cholesterol and a PEG-lipid (PEG-DMG) that directs the particle in vivo towards the liver hepatocytes [ 15 , 16 , 17 ]. The ionizable cationic lipid in the LNP complexes with the nucleic acids in acidic media (pH~4) by electrostatic interaction.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

et al. 2021

View full text Add to dashboard Cite

COVID-19 vaccines have been developed with unprecedented speed which would not have been possible without decades of fundamental research on delivery nanotechnology. Lipid-based nanoparticles have played a pivotal role in the successes of COVID-19 vaccines and many other nanomedicines, such as Doxil® and Onpattro®, and have therefore been considered as the frontrunner in nanoscale drug delivery systems. In this review, we aim to highlight the progress in the development of these lipid nanoparticles for various applications, ranging from cancer nanomedicines to COVID-19 vaccines. The lipid-based nanoparticles discussed in this review are liposomes, niosomes, transfersomes, solid lipid nanoparticles, and nanostructured lipid carriers. We particularly focus on the innovations that have obtained regulatory approval or that are in clinical trials. We also discuss the physicochemical properties required for specific applications, highlight the differences in requirements for the delivery of different cargos, and introduce current challenges that need further development. This review serves as a useful guideline for designing new lipid nanoparticles for both preventative and therapeutic vaccines including immunotherapies.

show abstract

Section: Lipid-based Nanoparticlesmentioning

confidence: 99%

Section: Lipid-based Nanoparticlesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Thus, NPs have been widely used as drug carriers for the treatment of liver fibrosis. Lipid-based NPs have been recognized as the most powerful vehicles because of their good biocompatibility and low toxicity ( Table 1 ) [ 69 ]. CCAAT/enhancer-binding protein alpha (CEBPA), a master transcriptional factor in the liver, resets the natural gene regulatory mechanism of hepatocytes to reduce fibrosis and reverse liver dysfunction.…”

Section: Nanomedicine For Liver Fibrosis Therapymentioning

confidence: 99%

Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis

Bai

Zhai

2020

Nanomaterials

View full text Add to dashboard Cite

Liver fibrosis, a reversible pathological process of inflammation and fiber deposition caused by chronic liver injury and can cause severe health complications, including liver failure, liver cirrhosis, and liver cancer. Traditional diagnostic methods and drug-based therapy have several limitations, such as lack of precision and inadequate therapeutic efficiency. As a medical application of nanotechnology, nanomedicine exhibits great potential for liver fibrosis diagnosis and therapy. Nanomedicine enhances imaging contrast and improves tissue penetration and cellular internalization; it simultaneously achieves targeted drug delivery, combined therapy, as well as diagnosis and therapy (i.e., theranostics). In this review, recent designs and development efforts of nanomedicine systems for the diagnosis, therapy, and theranostics of liver fibrosis are introduced. Relative to traditional methods, these nanomedicine systems generally demonstrate significant improvement in liver fibrosis treatment. Perspectives and challenges related to these nanomedicine systems translated from laboratory to clinical use are also discussed.

show abstract

“…Hepatic fi brosis is the excessive accumulation of Extra Cellular Matrix (ECM) protein including collagen in the liver attributed tothe trans-differentiation of HSC by fi brogenic cytokines such as This mini review focuses on surface engineering of organic lipid nanoparticles for the treatment of hepatic fi brosis via specifi c and un-specifi c HSC-targeting. Hyaluronic acid (HA), Chemokines receptor type 4 (CXCR4) and galactosyl receptor conjugated with several ligands like cRGD* peptide, C*GRGDSPC* peptide, M6P, cyclic C*SRNLIDC* peptide, RBP via direct coating or grafting(Table 1)[2,4].Biocompatible and bio-degradable surface engineered lipid nano carrier should have suffi cient internalization capacity by HSC, entrapment effi ciency, penetrating power to interact with HSC for the treatment of hepatic fi brosis. However, the delivery of drug and gene through lipid-based nano carrier is limited by intrinsic and biological barriers[2,4].Table 2 summarizesligand-based lipid nanoparticulate approaches for targeting HSC.…”

mentioning

confidence: 99%

Lipid nanoparticulate drug delivery system for the treatment of hepatic fibrosis

Mukherjee¹,

Ayon²,

Ash³

2021

Arch Hepat Res

View full text Add to dashboard Cite

HSC becomes a cellular target for the treatment of hepatic fi brosis [1]. Low therapeutic effi cacy and undesirable systemic effect of standard conventional therapies limit their clinical applications in this fi eld.Nano-material based drug delivery systems such as Lipid, polymeric, inorganic and protein nanoparticles have been shown an exceptional potential for novel therapeutic approaches to deliver anti-fi brotic nutrients

show abstract

Lipid-based nanoparticle technologies for liver targeting

Cited by 141 publications

References 253 publications

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis

Lipid nanoparticulate drug delivery system for the treatment of hepatic fibrosis

Contact Info

Product

Resources

About